News headlines about Qiagen (NASDAQ:QGEN) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Qiagen earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave media stories about the company an impact score of 47.5640270838404 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media stories that may have effected Accern’s analysis:
A number of equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Qiagen from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a research report on Tuesday, October 10th. Cowen restated a “hold” rating and set a $33.00 target price on shares of Qiagen in a research report on Friday, November 3rd. Commerzbank restated a “buy” rating on shares of Qiagen in a research report on Tuesday, November 7th. J P Morgan Chase & Co restated a “neutral” rating on shares of Qiagen in a research report on Tuesday, November 7th. Finally, Deutsche Bank restated a “buy” rating on shares of Qiagen in a research report on Friday. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $34.06.
Qiagen (NASDAQ:QGEN) traded down $0.43 during trading on Monday, reaching $31.24. 738,086 shares of the company were exchanged, compared to its average volume of 964,381. The stock has a market capitalization of $7,210.00, a P/E ratio of 25.75, a price-to-earnings-growth ratio of 1.94 and a beta of 1.10. The company has a current ratio of 5.33, a quick ratio of 4.78 and a debt-to-equity ratio of 0.68. Qiagen has a 52 week low of $27.51 and a 52 week high of $36.34.
Qiagen (NASDAQ:QGEN) last released its quarterly earnings results on Monday, November 6th. The company reported $0.32 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.32. The company had revenue of $364.00 million for the quarter, compared to the consensus estimate of $363.42 million. Qiagen had a net margin of 6.40% and a return on equity of 11.36%. Qiagen’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.29 earnings per share. sell-side analysts anticipate that Qiagen will post 1.25 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Qiagen (QGEN) Receives Media Sentiment Rating of 0.09” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/04/qiagen-n-v-qgen-getting-somewhat-positive-press-coverage-accern-reports.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.